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Inhibition of neutrophii superoxide production hy human plasma 
a,-antitrypsin 
Exposure of neutmphik to a variety of stimuli fin- 
&ding conunavalin A plus cytochalasi~ E) activates 
a membnne-bound NADPHoxidase to catalyst the 
gnemtion of the superoside anion radical (O;-t 
Rbhrr*rti~&s: q-AT. a,-antitrypsinr TPCK. L-l-tosylamide 3phenyl- 
ahyl chloromethyl ketone: SBTI. soybean tqpsin inhibitor: Con A. 
connnovalin A: Cyto E. cytochalasin E. 
Corwsp~rrdc~~~ a&rcs: P.G. Winyard. Ictlammation Rewarch 
Group. Arthritis and Rheumatism Council Buildmg. Lczdon Hospi- 
tal Medical College. Z-29 AshficldStrcct, Londcn Ei 2.4D. Err&ml. 
Fax {44) (7:) 377 M??. 
During the course of eqxrintenrs designed to study 
the mcvhanisms of a,-AT inactivation by isolared 
huma‘; neutrophi8 WC noted that rhc amaunt of de- 
tecloblc CrT* relcascd by cel!s stimulazed with a vari~ig 
of agents :wru,s~-&ed qmosan. nhziom ionophow 
Or SiX’YZXNaliFS A fCkX r’ ’ .;w qK.&Gx? E :cg:c 
E)) was Iowrcd in the pxencc of q-AT. Eulicr swi- 
ils. which wrc largely performed with Con A + Cyto 
E as the slimulus. showed that L-I-tosylamide 2-phenyl- 
cth>l chlommethyl ketone IT&X). soybean trypsia in- 
hibitor (SBTU and other sMinc pmtease inhibitors have 
the ability to inhibit cX_- production by neutmphils(Wl 
and references therein) and by other cefl QF j15.161. 
Therefore. the dose-dependent inhibition by at-AT of 
Con A + C’)TO E-stimulated neutrophil a- production 
was cornpar& wi\?rh the dose responses for TPCK, SBTI 
and q-AT-A&*_ The latter is a human recombinant 
X,-AT vntiant in which the reactive centre Met”’ has 
k;; q+~&ss ;ay an aqinine residue [I 7]_ Thii single 
amino acid substitution results in a 10.~fold dc- 
crease in anti-CLasroly-tic activity and a 1O.OWfold in- 
cww ir? &rnmzhin inhibitory capacity. 
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stiniulntory i\gClllS only) end one ns 11 ncgnlivc conwol (Cells + sliinu- 
latory tiycnts + supcroxidc dismuturic). 
The unwunt of0;’ produced (nmol O,‘U/lOh wlls) wits d~ulutcd 
using nn cxlinction cdlkdcnt 01’21 I( 10’ M” ‘*cm”’ id plottd us II 
limainn ol’ thno ul\cr rrddhian ol’rdmulimtr to obtnin the inhid nltc 
01’ cxh rcnction. The inhibitory ca~pncity wus onlculu~cd aY the % 
inhihhion 01’ the inill:\! nW oT the posilivc cannnl. 
3. RESULTS 
e,=AT, TPCK und SBTt showed vrrrious &grees of 
inhibition of the ncutrophil Oi* production clicitd by 
serum-trcutcd zymosun, culcium ionophorc A 23187 
and Con A plus Cyta E (Tnblc I). Whatcvcr the tri 
ing agent, siynilicunt umounts of inhibition wcrc o 
tuincd with both a,AT and TPCK ut similrir molnr 
conentratians (11.3 ~md 10.0yM, rqxdvcly). HOW- 
cvcr, t’or SBTI, the molnr conccntrution rcquipcd to ivc 
tdmih\r extents cd’ inhibition was about ?Wold higher 
(Tublc I). 
a,-AT at n cxxtccntrution of 0.6 mg/ml (IL5 pM) 
ulnmt complctcly inhibit& O<- rdcnsc brn human 
ncutrophils stimulutd with Con A + Qto E. Fii. I 
shows the results of n typicrrl experiment. The inhibition 
wns dasc-dcpcndcnt Kurd wns still signitkunt ut 5.2 mg?l 
ml (3.8 PM). 
a,-AT-ArglJn showed no cffit over the rtff’cctiw &WC 
riuuc of al-AT. At high Lvrnecntrntions G 
pro&d some inhibition (I 15 JJM gave IL 
tion) (Fig. 2). Two scrinc protcase inhibitors fTPCK 
und SBT\) tcstd showed dose-rcsponsc cn’ccts similar 
to those previously ohtriincd by Kitugwu and co- 
workers 11 S] (Fig. 2). The cxxxcntrution mngc used was 
0.2-10@4 for TPCK and 1004OOpM for SBTL Table 
II sho\\Ts the ii; WIUCS (conccntmtion rcquinxi for 50% 
inhibition of 02’- production) for the four sctinc pro- 
tci\sc inhibitorx or,-mtitrypsin has n K, lower than SBTl 
ittld similar t0 TPCK. 
The scrinc prwtwsc inhihitn:: tcskd hiId ~‘1 vgtotosis 
vI 50 I~_._. - -, .--- I- _  .; 
TIME AFTER STIMULANT ALYDITION (MN) 
Fig. 1. Time COUIW of thu inhibitory cffcct 01’ r;i,-iudqpsin on Cl;‘- 
P:OdllctiO~i by stimulatd human ncutrophik ( ) Con A -r Cyto E 
idonc: (W 3.X pM a,-AT; (Et!) 5.7 PM n,-AT; (A) Il.5 PM a,-AT. 
Volume 300, number I FEBS LETTERS March 1992 
WC haw show tbar at sub-ph)riiological concentra- 
Cons a,-AT inhibits the axidative burst ot’ stimulated 
neutrophils_ For comparison. the conccntntion of a,- 
AT in both normal humzln plasm and knee-joint sy- 
n&al fluid from rheumatoid arthritis patients is about 
3 -5 mg:‘rd, although in a\wag &out 40% o!’ the aI- 
,4T in rlrsumaoid .xthtitis syt’tovil fluid is ina&o [-Cl. 
al-AT-A&? which has r&tia~Iy u;cak anti-&&use 
activity compared with a,-AT. only inhibited neutrophil 
CL- p~&~~~iun at high concentrations, suggesting that 
th’& elTwt was related to protease inhibitoq ~apacitg. 
This interpretation is further sustained by the lack of 
Table tl 
K, (concentration required for 50% inhibition of WA production) of 
.smine pro1ea.w Inhibitors in Con A + QIO E-triggcml O,‘- n&w b> 
human ncuwophih. Values uplp cdcukt~cd form Fig. 2. 
Serine protease inhibitor 
- 
a,-A-l- 5.1 (_uhl) 
a,-AT-Arg”” 93.6 (UN! 
TPCK 4.7 yrhij 
SBTI ~07.0 (UhS) 
--- 
0;” =Wqting capacity of alI the inhibitors tc.stai. In 
umcmcnt with previous results (Is]. ~M~IIC protea* 
inhibiton which arc not members of the srpin protein 
suprRmily also inhibited neutrophi~ Q’- pdwtion, 
The high molecular wcilqht inhibitor af ttypsin (SBTI) 
rend the low molecular wight inhibitor ofchymotrypin 
(TKK? uct by inhibiting zt ncutrophil plrsrm~ 
membrrrne trypGt&hym~~ - 
bxcnt~y, Kilp&tzk ct 
-like prt+a!x [r q. 
rrplnrcd the inhit* 
of hmn 
@p&n, workce m&an thirt a c0mu~~4 
Pwumt at-AT ISi) bird no inhiBitw &ct 
it concentr&xtn txqin ftxam Q,i to t60 JlhR. fhis 
discrepancy 1 bc @xounled fw by a difference in 
the activitiez4 at-AT pnzpawtiQn USXI in thii aztu$y 
und that US& by k;ilp~&~k ~3 cewotken_ 
ier studies in which ncutrq&iP 
&&ttive inactintian of’ al-AT 
tf0 (fi=bF C-!UMRl~tc! pal,. the cxI11- 
cxntratiam oFa,-AT would hue been to9 low to if- 
icrtntly inhibit Q+- pradu&xt. The a,*AT cwcettm- 
tions used in these eqxrifwn Cd the -lm* 
rian rqyr in bmnch~lve& 
p@mlt. Pl0Wevcr. in some i 
q-AT cvncentmtion in much h 
wrthrith ay~ovial fluid. In 
twphits were incubat4 with a,-AT at mtratian$ in 
this higher range, the a,cAT ~‘8s ci&er not is direct 
c%ntact with rite cxlla e.g, wmpwtmentat in &lysis 
tubing in tlw prclscnce of e.Rtcm& stimukwd neu- 
trophib &Sl) or. the al-AT VW irutctiwtrd by the addi- 
tion of a supermeant which hvld been conditioned by 
stimufatcd neutrophils 1 t t 25). 
WC conclude that. in inf!ammatory fluids contzzining 
rclatiwly high concentrations of q-AT. this serpin 
might play a physiological role in directly inhibiting 
ncutrophil 02*- production. Although it might bc 
argued &at the stiz~ulus mSnly used in this study Con 
A c Cyu E) is not physiclogiilly F? =nt. other stud- 
&. #SC refc;Tzncx.s ciiic : {I SJ] as WCE JS cur twn rcsui~~ 
obaind with serum-trcatcd zynosan and calcium iw 
nophon- show that wine protcasc inhibitors inhibit 
wutrophil cX_ production in response to a variet)’ of 
stimuli. Ektstase h;ls been shown to print neutrophil 
02*- release dited by dininxtt stimulants [XXI. Our 
experimental system contained no added elastase 10 
prime the system prior to stimulant addition. suggesting 
that a,-AT inhibited neutrophil C&- release by inhibit- 
ing a membmne bound wine protease. HOWWW. in 
viva. inhibition of elastase may be an additional mcch- 
anism by which q-AT down-regulates the neutrophil 
wi;arive wsponse. 
our ~~ufts also suggest hat. in those inflammatory 
&ids where the q-AT concentration is relatively hi& 
th:L oxidation of a,-AT by neutrophil-released rcactiw 
o~~g~u ;+&s is unlikely tc occur. However. other cc;1 
typ may mediate the oxidation of a,-AT and it ‘5 
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